Diamond Equity Research Initiates Coverage on Genprex Inc.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
110
Diamond Equity Research Initiates Coverage on Genprex Inc. (NASDAQ: GNPX) with a Valuation of $13 Per Share

NEW YORK, July 02, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Diamond Equity Research, a leading equity research and corporate access firm with a focus on small capitalization public companies has initiated coverage of Genprex Inc. (NASDAQ: GNPX ). The in-depth 27-page initiation report includes detailed information on Genprex 's business model, services, industry, valuation, management, and risks.

The full research report is available  here . Highlights from the report include:

Large Market Opportunity

Genprex is a clinical stage gene therapy company developing a novel approach to cancer treatment, with its initial product candidate targeting lung cancer. According to the World Health Organization, there are over 1.8 million new lung cancer patients and 1.6 million deaths from lung cancer worldwide [1]. Among these cases, approximately 80 percent were Non-Small Cell Lung Cancer (NSCLC). Genprex is targeting the NSCLC market with its Oncoprex™ immunogene therapy or Oncoprex™. With lung cancer continuing to be the leading cause of cancer related death in the world, new treatment options are critical, with Genprex potentially offering a novel treatment option for patients.

Genprex’s lead product, Oncoprex™, has completed its Phase I clinical trial and is currently conducting a Phase II trial.  To date, the response rate and disease control rate in the Phase II portion of the company’s Phase I/II clinical trial substantially exceeded the response rate of 7 percent (with no CRs) and disease control rate of 58 percent reported for a clinical trial of the TKI afatinib (marketed as Gilotrif® by Boehringer Ingelheim Pharmaceuticals, Inc.) in a study referred to as the LUX-Lung 1 clinical trial [1].

In a recent company update, Julien L. Pham, MD, MPH, President and Chief Operating Officer, stated, " We believe that Oncoprex™ may provide medical benefit in several subpopulations of NSCLC for which there is an unmet medical need and may provide pathways for expedited approval by the FDA."

Unique Cancer Treatment Approach

Genprex is developing an innovative and unique approach to treating lung cancer by administering cancer fighting genes in nanoscale hollow spheres called nanovesicles. Genprex has a multimodal mechanism of action which interrupts cell signaling pathways responsible for the spread of cancer. Oncoprex™ also potentially can block various mechanisms which result in drug resistance.

Attractive Valuation

It is very difficult to value Genprex Inc. given its early stage and the limited number of public listed companies engaged in the development of immunogene therapies for non-small cell lung cancer (NSCLC). In our technology value analysis, we selected small capitalization companies within the biotechnology industry targeting similar indications and at similar stages of development. We estimated a forward-looking market value using the peer group average and median market value of each unique drug in their clinical trial stages. We also built a top down model and discounted cash flow to value Genprex. From our analysis, we found the shares to be undervalued with significant upside from current trading levels. Based on an average of the two methods, we computed a valuation of $13 per share, indicating the stock is undervalued.

About Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company developing a new approach to treating cancer, based on the novel proprietary technology platform, including its initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). The company was founded in 2009 and is headquartered in Austin, Texas.

For more information, visit  http://ir.genprex.com/ .

About Diamond Equity Research

Diamond Equity Research is a leading equity research and corporate access firm focused on small capitalization companies. Diamond Equity Research is an approved sell-side provider on premiere institutional investor platforms including Factset, Morningstar, and Thomson One. The founder, Hunter Diamond, CFA, brings extensive experience working as a research analyst and investment banker focused on emerging growth companies. Hunter Diamond, CFA holds his Bachelor of Science and Master of Business Administration from Cornell University. The firm is headquartered in midtown Manhattan.

For more information, visit  www.diamondequityresearch.com .

Disclosures:

Full disclosures pertaining to this report can be found at the end of the report and on the Diamond Equity Research website disclosure section. Genprex Inc. has paid for this report as company sponsored research, which is meant to subsidize the high cost of creating the report and monitoring the security, however the views in the report reflect that of Diamond Equity Research. Diamond Equity Research LLC is being compensated by Genprex Inc. for producing research material consisting of an initiation research report regarding Genprex Inc. and its securities over a one-month period. All payments are received upfront. As of 07/02/2018 the issuer had paid us $10,500 for our services, which commenced 06/11/2018. Additional fees may have accrued since then.

Contact:

Hunter Diamond, CFA Diamond Equity Research research@diamondequityresearch.com

1. Varner, R. (2018, June 15). Amendment No. 1 to Form S-1. Retrieved from https://www.sec.gov/Archives/edgar/data/15952...1a.htm  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading

Top 5 Most Recently Viewed Articles

Westlake Chemical Partners Schedules Q4 and Year-End Call

Updated Category News Views 158

Westlake Chemical Partners to Announce Earnings Soon Westlake Chemical Partners (NYSE: WLKP), based in Houston, is preparing to release its earnings report for the fourth quarter and full year 2024. This significant announcement is eagerly anticipated by investors and industry analysts alike. The earnings report is scheduled to be released prior to the market opening on a...

Continue Reading
Wabtec's Bold Move: Acquiring Evident's Tech Division

Updated Category News Views 144

Wabtec's Strategic Acquisition of Evident's Inspection Technologies Wabtec Corp, a leader in heavy industrial parts manufacturing, has made headlines with its recent decision to acquire the inspection technologies division of Evident for an impressive $1.78 billion. This acquisition reflects Wabtec's strategy to enhance its portfolio and strengthen its position within the...

Continue Reading
Insight into WisdomTree's Latest Fund Valuations

Updated Category News Views 184

Understanding Net Asset Values in ETFs Investors often seek knowledge about the net asset values (NAVs) of Exchange Traded Funds (ETFs), which play a critical role in determining how funds are valued and traded in the market. For instance, WisdomTree Issuer plc regularly offers updates concerning its funds, revealing the intricate details behind price fluctuations and...

Continue Reading
Investigation Announced Into Electronic Systems Technology, Inc.

Updated Category News Views 239

Investigation of Electronic Systems Technology, Inc. In a noteworthy development, the M&A Class Action Firm has announced an investigation into Electronic Systems Technology, Inc. (OTCMKTS: ELST). This firm, recognized as a top competitor in the 2024 ISS Securities Class Action Services Report, is dedicated to protecting shareholder interests. The firm, led by renowned...

Continue Reading
Fusion CBD Products Partners with Major League Baseball Teams

Updated Category News Views 291

Fusion CBD Products and Major League Baseball: A Growing Partnership Team sponsorship opportunities expand as the league embraces CBD's advantages. As the Major League Baseball (MLB) season unfolds, many players are facing injuries from early training sessions and games. Notable players like Heliot Ramos of the San Francisco Giants and Erik Miller have recently dealt with...

Continue Reading